NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Azenosertib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
Azenosertib
DrugBank Accession Number
DB18028
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 526.645
Monoisotopic: 526.280472367
Chemical Formula
C29H34N8O2
Synonyms
  • 3h-pyrazolo(3,4-d)pyrimidin-3-one, 1-((7r)-7-ethyl-6,7-dihydro-7-hydroxy-5h-cyclopenta(b)pyridin-2-yl)-1,2-dihydro-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)-
External IDs
  • ZN-C3
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9J13XU96Z1
CAS number
2376146-48-2
InChI Key
OXTSYWDBUVRXFF-GDLZYMKVSA-N
InChI
InChI=1S/C29H34N8O2/c1-4-14-36-27(38)23-19-30-28(31-21-7-9-22(10-8-21)35-17-15-34(3)16-18-35)33-26(23)37(36)24-11-6-20-12-13-29(39,5-2)25(20)32-24/h4,6-11,19,39H,1,5,12-18H2,2-3H3,(H,30,31,33)/t29-/m0/s1
IUPAC Name
1-[(7R)-7-ethyl-7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-3-one
SMILES
CC[C@@]1(O)CCC2=CC=C(N=C12)N1N(CC=C)C(=O)C2=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C12

References

General References
Not Available
ChemSpider
114826635
ChEMBL
CHEMBL5095036
PDBe Ligand
05J
PDB Entries
7n3u

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
2Active Not RecruitingTreatmentHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer1somestatusstop reasonjust information to hide
2Active Not RecruitingTreatmentUterine Serous Carcinoma1somestatusstop reasonjust information to hide
2Not Yet RecruitingTreatmentUterine Carcinoma / Uterine Malignancies / Uterine Serous Carcinoma1somestatusstop reasonjust information to hide
2RecruitingTreatmentAdvanced Pancreatic Adenocarcinoma / Pancreatic Cancer / Pancreatic Ductal Adenocarcinoma (PDAC)1somestatusstop reasonjust information to hide
1Not Yet RecruitingTreatmentClinical Stage III Gastric Cancer AJCC v8 / Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IV Gastric Cancer AJCC v8 / Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 / Locally Advanced Gastric Carcinoma / Locally Advanced Gastroesophageal Junction Adenocarcinoma / Locally Advanced Malignant Solid Neoplasm / Metastatic Gastric carcinoma / Metastatic Gastroesophageal Junction Adenocarcinoma / Metastatic Malignant Solid Neoplasms / Unresectable Gastric Carcinoma / Unresectable Gastroesophageal Junction Adenocarcinoma / Unresectable Malignant Solid Neoplasm1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP3.68Chemaxon
pKa (Strongest Acidic)13.36Chemaxon
pKa (Strongest Basic)8.72Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area100.96 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity163.63 m3·mol-1Chemaxon
Polarizability59.1 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 08, 2023 03:16 / Updated at September 12, 2023 18:32